Wellesley, MA – According to filings with the U.S. Securities and Exchange Commission, Janus Biotherapeutics is raising $4,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Joseph Baron played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Janus Biotherapeutics

Janus Biotherapeutics is an autoimmunity therapeutics company dedicated to the development of novel, orally available compounds for the treatment of autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, Sjogren’s syndrome, psoriasis, and scleroderma.

To learn more about Janus Biotherapeutics, visit http://janusbio.com/

Contact:
Joseph Baron, Chief Executive Officer
781-591-8927
https://www.linkedin.com/in/joseph-baron-26071/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved